<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="letter">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Emerg Infect Dis</journal-id>
      <journal-id journal-id-type="iso-abbrev">Emerging Infect. Dis</journal-id>
      <journal-id journal-id-type="publisher-id">EID</journal-id>
      <journal-title-group>
        <journal-title>Emerging Infectious Diseases</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">1080-6040</issn>
      <issn pub-type="epub">1080-6059</issn>
      <publisher>
        <publisher-name>Centers for Disease Control and Prevention</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">26890501</article-id>
      <article-id pub-id-type="pmc">4766891</article-id>
      <article-id pub-id-type="publisher-id">15-1479</article-id>
      <article-id pub-id-type="doi">10.3201/eid2203.151479</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Letters to the Editor</subject>
        </subj-group>
        <subj-group subj-group-type="article-type">
          <subject>Letter</subject>
        </subj-group>
        <subj-group subj-group-type="TOC-title">
          <subject><italic>Mycobacterium arupense</italic> as an Emerging Cause of Tenosynovitis</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title><italic>Mycobacterium arupense</italic> as an Emerging Cause of Tenosynovitis</article-title>
        <alt-title alt-title-type="running-head"><italic>Mycobacterium arupense</italic> Tenosynovitis</alt-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>Lopez</surname>
            <given-names>Fiorella Krapp</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Miley</surname>
            <given-names>Madeline</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Taiwo</surname>
            <given-names>Babafemi</given-names>
          </name>
        </contrib>
        <aff id="aff1">Northwestern University, Chicago, Illinois, USA (F. Krapp Lopez, B. Taiwo); </aff>
        <aff id="aff2">Northwestern Memorial Hospital, Chicago (M. Miley)</aff>
      </contrib-group>
      <author-notes>
        <corresp id="cor1">Address for correspondence: Fiorella Krapp Lopez, Division of Infectious Diseases, Department of Medicine, Northwestern University, 645 N Michigan Ave, Ste 900, Chicago, IL 60611, USA; email: <email xlink:href="fiorella.krapp@northwestern.edu">fiorella.krapp@northwestern.edu</email></corresp>
      </author-notes>
      <pub-date pub-type="ppub">
        <month>3</month>
        <year>2016</year>
      </pub-date>
      <volume>22</volume>
      <issue>3</issue>
      <fpage>559</fpage>
      <lpage>561</lpage>
      <kwd-group kwd-group-type="author">
        <title>Keywords: </title>
        <kwd>
          <italic>Mycobacterium arupense</italic>
        </kwd>
        <kwd>nontuberculous <italic>Mycobacterium</italic> infections</kwd>
        <kwd>tenosynovitis</kwd>
        <kwd>canakinumab</kwd>
        <kwd>corticosteroids</kwd>
        <kwd>tuberculosis and other mycobacteria</kwd>
        <kwd>bacteria</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <p><bold>To the Editor:</bold>
<italic>Mycobacterium arupense</italic> was identified in 2006 as a novel species within the <italic>M. terrae</italic> complex with close similarity to <italic>M. nonchromogenicum</italic> (<xref rid="R1" ref-type="bibr"><italic>1</italic></xref>). Since then, 8 cases describing clinically notable disease have been published (<xref rid="R2" ref-type="bibr"><italic>2</italic></xref>&#x2013;<xref rid="R8" ref-type="bibr"><italic>8</italic></xref>), including 5 cases of tenosynovitis. We report <italic>M. arupense</italic> tenosynovitis in an immunocompromised person who received the selective interleukin (IL) 1 &#x3B2;-inhibitor canakinumab.</p>
    <p>In July 2014, a 62-year-old man sought treatment at the emergency department, Northwestern Memorial Hospital (Chicago, Illinois, USA), after 1 week of pain and swelling in the right hand. During the previous 5 years, he had received multiple immunomodulatory drugs for treatment of natural killer cell deficiency, hyper&#x2013;IL-6 syndrome, recurrent polychondritis, and Sweet syndrome. His medications were prednisone (42.5 mg/d), intravenous immunoglobulin (400 mg/kg monthly), and subcutaneous canakinumab (180 mg every 8 weeks, which began 3 weeks before onset of symptoms).</p>
    <p>His first symptom was a tender red nodule on the right palm that increased in size and became extremely tender over the following week (<xref ref-type="fig" rid="F1">Figure</xref>, panels A, B). He did not recall any trauma and denied fever or chills. No improvement was seen after he received oral linezolid for 5 days. A skin punch biopsy specimen showed a neutrophilic interstitial infiltrate with no granulomas; results of microbiological stains, including acid-fast bacilli, were negative, . His prednisone dosage was increased to 60 mg/d for suspected Sweet syndrome and, subsequently, to 80 mg/d when no improvement was observed after 2 weeks. A second dose of canakinumab was administered 8 weeks after the first. Shortly after, he was readmitted to the hospital with progression of edema and pain and signs consistent with carpal tunnel syndrome and trigger finger syndrome of the right index finger. Magnetic resonance imaging showed extensive tenosynovitis of the carpal tunnel flexor tendons and no bone erosions. Surgical release and tenosynovectomy of the carpal tunnel was performed; pathologic features demonstrated chronic inflammation of the synovium and absence of granulomas. Results of microbiological stains were negative.</p>
    <fig id="F1" fig-type="figure" position="float">
      <label>Figure</label>
      <caption>
        <p>Hands of a 62-year-old man in Chicago, Illinois, USA, who had <italic>Mycobacterium arupense</italic> tenosynovitis, at the time treatment was sought (panels A, B) and after 6 months of treatment (panels C, D).</p>
      </caption>
      <graphic xlink:href="15-1479-F"/>
    </fig>
    <p><italic>M. arupense</italic> grew on L&#xF6;wenstein-Jensen culture from the skin biopsy specimen after 35 days and from a synovium specimen after 22 days. No growth was observed on liquid culture media. Empiric treatment was started immediately after the first positive culture: clarithromycin (500 mg 2&#xD7;/d), ethambutol (1,200 mg/d), and rifabutin (300 mg/d). Prednisone was decreased to 45 mg/d, and canakinumab was discontinued. Susceptibility testing confirmed the <italic>M. arupense</italic> strain&#x2019;s susceptibility to clarithromycin, ethambutol, and rifabutin (MICs &lt;4.0, &lt;1.25, and &lt;0.12, respectively); intermediate resistance to rifampin and amikacin (MIC 4.0); and resistance to moxifloxacin and ciprofloxacin (MIC &gt;4.0) and to kanamycin (MIC &gt;8.0). Clinical improvement occurred after 8 weeks of treatment; the condition resolved after 6 months (Figure, panels C, D). Treatment was continued for 12 months.</p>
    <p>Five other cases of <italic>M. arupense</italic> tenosynovitis have been reported (<xref rid="R2" ref-type="bibr"><italic>2</italic></xref>,<xref rid="R4" ref-type="bibr"><italic>4</italic></xref>,<xref rid="R5" ref-type="bibr"><italic>5</italic></xref>,<xref rid="R7" ref-type="bibr"><italic>7</italic></xref>,<xref rid="R8" ref-type="bibr"><italic>8</italic></xref>); all patients were immunocompetent or minimally immunocompromised (i.e., diabetes mellitus) (<xref ref-type="local-data" rid="SD1">Technical Appendix</xref>). The hand was the site of infection in all cases, and 4 of 5 patients reported prior trauma to the affected area, which suggests that inoculation was the infection mechanism. In the case we describe, the disease appeared to progress much faster than in the immunocompetent patients (weeks vs. months to years). Acid-fast bacilli stain was negative in all of the cases where it was performed (<xref rid="R2" ref-type="bibr"><italic>2</italic></xref><italic>,</italic><xref rid="R7" ref-type="bibr"><italic>7</italic></xref><italic>,</italic><xref rid="R8" ref-type="bibr"><italic>8</italic></xref>; this study), and growth on solid L&#xF6;wenstein-Jensen stain or Middlebrook media was seen after a prolonged incubation time, ranging from 27 days to 2 months. Liquid culture media appears to be unreliable for the growth of <italic>M. arupense</italic> (<xref rid="R8" ref-type="bibr"><italic>8</italic></xref>; this study).</p>
    <p>A combination of tenosynovectomy and prolonged antimycobacterial treatment, guided by in vitro strain susceptibility, was used in all the reported cases; a positive outcome was achieved in 6&#x2013;14 months. The strain susceptibility results we found are comparable with those in the previous cases, showing consistent susceptibility to clarithromycin, ethambutol, and rifabutin; variable susceptibility to linezolid, streptomycin, and amikacin; and resistance to rifampin and quinolones.</p>
    <p>Two cases of <italic>M. arupense</italic> infection have been reported in immunosuppressed persons, both in HIV/AIDS patients (manifesting as pulmonary infection in 1 patient and disseminated disease in the other) (<xref rid="R6" ref-type="bibr"><italic>6</italic></xref>). In our study, the immunocompromised patient with <italic>M. arupense</italic> tenosynovitis received canakinumab, a relatively new biologic agent with a prolonged selective IL-1 &#x3B2;-blockade. Even though the contribution of canakinumab in this case is confounded by concomitant immune deficiencies (natural killer cell deficiency, high-dose corticosteroids), the temporal association between initiation of canakinumab and the onset of symptoms raises concern of a possible association. Animal studies have shown that IL-1 plays a key role in host resistance to mycobacterial infections by regulating Th1/Th2 immune responses and inducing granuloma formation (<xref rid="R9" ref-type="bibr"><italic>9</italic></xref>). Clinical trials and systematic reviews assessing the safety of IL-1 inhibitors, including anakinra, rilonacept, and canakinumab, have not shown that these drugs lead to an increased risk of tuberculosis or other mycobacterial infections (<xref rid="R10" ref-type="bibr"><italic>10</italic></xref>). Nonetheless, our report provides increased evidence that <italic>M. arupense</italic> is an emerging cause of tenosynovitis and that it is potentially associated with immunosuppression.</p>
    <supplementary-material content-type="local-data" id="SD1">
      <caption>
        <title>Technical Appendix</title>
        <p>Clinical characteristics and microbiological and treatment characteristics of case-patients with <italic>Mycobacterium arupense</italic> tenosynovitis in published reports.</p>
      </caption>
      <media mimetype="application" mime-subtype="pdf" xlink:href="15-1479-Techapp-s1.pdf" xlink:type="simple" id="d36e248" position="anchor"/>
    </supplementary-material>
  </body>
  <back>
    <fn-group>
      <fn fn-type="citation">
        <p><italic>Suggested citation for this article</italic>: Krapp Lopez F, Miley M, Taiwo B. <italic>Mycobacterium arupense</italic> as an emerging cause of tenosynovitis. Emerg Infect Dis. 2016 Mar [<italic>date cited</italic>]. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.3201/eid2203.151479">http://dx.doi.org/10.3201/eid2203.151479</ext-link></p>
      </fn>
    </fn-group>
    <ref-list>
      <title>References</title>
      <ref id="R1">
        <label>1. </label>
        <mixed-citation publication-type="journal"><string-name><surname>Cloud</surname>
<given-names>JL</given-names></string-name>, <string-name><surname>Meyer</surname>
<given-names>JJ</given-names></string-name>, <string-name><surname>Pounder</surname>
<given-names>JI</given-names></string-name>, <string-name><surname>Jost</surname>
<given-names>KC</given-names>
<suffix>Jr</suffix></string-name>, <string-name><surname>Sweeney</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Carroll</surname>
<given-names>KC</given-names></string-name>, <etal/>
<article-title><italic>Mycobacterium arupense</italic> sp. nov., a non-chromogenic bacterium isolated from clinical specimens.</article-title>
<source>Int J Syst Evol Microbiol</source>. <year>2006</year>;<volume>56</volume>:<fpage>1413</fpage>&#x2013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1099/ijs.0.64194-0</pub-id><pub-id pub-id-type="pmid">16738122</pub-id></mixed-citation>
      </ref>
      <ref id="R2">
        <label>2. </label>
        <mixed-citation publication-type="journal"><string-name><surname>Tsai</surname>
<given-names>TF</given-names></string-name>, <string-name><surname>Lai</surname>
<given-names>CC</given-names></string-name>, <string-name><surname>Tsai</surname>
<given-names>IC</given-names></string-name>, <string-name><surname>Chang</surname>
<given-names>CH</given-names></string-name>, <string-name><surname>Hsiao</surname>
<given-names>CH</given-names></string-name>, <string-name><surname>Hsueh</surname>
<given-names>PR</given-names></string-name>. <article-title>Tenosynovitis caused by <italic>Mycobacterium arupense</italic> in a patient with diabetes mellitus.</article-title>
<source>Clin Infect Dis</source>. <year>2008</year>;<volume>47</volume>:<fpage>861</fpage>&#x2013;<lpage>3</lpage>. <pub-id pub-id-type="doi">10.1086/591281</pub-id><pub-id pub-id-type="pmid">18713040</pub-id></mixed-citation>
      </ref>
      <ref id="R3">
        <label>3. </label>
        <mixed-citation publication-type="journal"><string-name><surname>Neonakis</surname>
<given-names>IK</given-names></string-name>, <string-name><surname>Gitti</surname>
<given-names>Z</given-names></string-name>, <string-name><surname>Kontos</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Baritaki</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Petinaki</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Baritaki</surname>
<given-names>M</given-names></string-name>, <etal/>
<article-title>Mycobacterium arupense pulmonary infection: antibiotic resistance and restriction fragment length polymorphism analysis.</article-title>
<source>Indian J Med Microbiol</source>. <year>2010</year>;<volume>28</volume>:<fpage>173</fpage>&#x2013;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.4103/0255-0857.62502</pub-id><pub-id pub-id-type="pmid">20404471</pub-id></mixed-citation>
      </ref>
      <ref id="R4">
        <label>4. </label>
        <mixed-citation publication-type="journal"><string-name><surname>Senda</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Muro</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Terada</surname>
<given-names>S</given-names></string-name>. <article-title>Flexor tenosynovitis caused by <italic>Mycobacterium arupense.</italic></article-title>
<source>J Hand Surg Eur Vol</source>. <year>2011</year>;<volume>36</volume>:<fpage>72</fpage>&#x2013;<lpage>3</lpage>. <pub-id pub-id-type="doi">10.1177/1753193410381825</pub-id><pub-id pub-id-type="pmid">21169302</pub-id></mixed-citation>
      </ref>
      <ref id="R5">
        <label>5. </label>
        <mixed-citation publication-type="journal"><string-name><surname>Legout</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Ettahar</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Massongo</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Veziris</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Ajana</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Beltrand</surname>
<given-names>E</given-names></string-name>, <etal/>
<article-title>Osteomyelitis of the wrist caused by <italic>Mycobacterium arup</italic>ense in an immunocompetent patient: a unique case.</article-title>
<source>Int J Infect Dis</source>. <year>2012</year>;<volume>16</volume>:<fpage>e761</fpage>&#x2013;<lpage>2</lpage>. <pub-id pub-id-type="doi">10.1016/j.ijid.2012.05.007</pub-id><pub-id pub-id-type="pmid">22809581</pub-id></mixed-citation>
      </ref>
      <ref id="R6">
        <label>6. </label>
        <mixed-citation publication-type="journal"><string-name><surname>Heidarieh</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Hashemi-Shahraki</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Khosravi</surname>
<given-names>AD</given-names></string-name>, <string-name><surname>Zaker-Boustanabad</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Shojaei</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Feizabadi</surname>
<given-names>MM</given-names></string-name>. <article-title><italic>Mycobacterium arupense</italic> infection in HIV-infected patients from Iran.</article-title>
<source>Int J STD AIDS</source>. <year>2013</year>;<volume>24</volume>:<fpage>485</fpage>&#x2013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1177/0956462412472818</pub-id><pub-id pub-id-type="pmid">23970753</pub-id></mixed-citation>
      </ref>
      <ref id="R7">
        <label>7. </label>
        <mixed-citation publication-type="webpage"><string-name><surname>Lee</surname>
<given-names>SJ</given-names></string-name>, <string-name><surname>Hong</surname>
<given-names>SK</given-names></string-name>, <string-name><surname>Park</surname>
<given-names>SS</given-names></string-name>, <string-name><surname>Kim</surname>
<given-names>EC</given-names></string-name>. First Korean case of <italic>Mycobacterium arupense</italic> tenosynovitis. Ann Lab Med. <year>2014</year>;34:321&#x2013;4.</mixed-citation>
      </ref>
      <ref id="R8">
        <label>8. </label>
        <mixed-citation publication-type="journal"><string-name><surname>Beam</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Vasoo</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Simner</surname>
<given-names>PJ</given-names></string-name>, <string-name><surname>Rizzo</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Mason</surname>
<given-names>EL</given-names></string-name>, <string-name><surname>Walker</surname>
<given-names>RC</given-names></string-name>, <etal/>
<article-title><italic>Mycobacterium arupense</italic> flexor tenosynovitis: case report and review of antimicrobial susceptibility profiles for 40 clinical isolates.</article-title>
<source>J Clin Microbiol</source>. <year>2014</year>;<volume>52</volume>:<fpage>2706</fpage>&#x2013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1128/JCM.00277-14</pub-id><pub-id pub-id-type="pmid">24789193</pub-id></mixed-citation>
      </ref>
      <ref id="R9">
        <label>9. </label>
        <mixed-citation publication-type="journal"><string-name><surname>Mayer-Barber</surname>
<given-names>KD</given-names></string-name>, <string-name><surname>Barber</surname>
<given-names>DL</given-names></string-name>, <string-name><surname>Shenderov</surname>
<given-names>K</given-names></string-name>, <string-name><surname>White</surname>
<given-names>SD</given-names></string-name>, <string-name><surname>Wilson</surname>
<given-names>MS</given-names></string-name>, <string-name><surname>Cheever</surname>
<given-names>A</given-names></string-name>, <etal/>
<article-title>Caspase-1 independent IL-1 beta production is critical for host resistance to <italic>Mycobacterium tuberculosis</italic> and does not require TLR signaling in vivo.</article-title>
<source>J Immunol</source>. <year>2010</year>;<volume>184</volume>:<fpage>3326</fpage>&#x2013;<lpage>30</lpage>. <pub-id pub-id-type="doi">10.4049/jimmunol.0904189</pub-id><pub-id pub-id-type="pmid">20200276</pub-id></mixed-citation>
      </ref>
      <ref id="R10">
        <label>10. </label>
        <mixed-citation publication-type="journal"><string-name><surname>Cantarini</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Lopalco</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Caso</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Costa</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Iannone</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Lapadula</surname>
<given-names>G</given-names></string-name>, <etal/>
<article-title>Effectiveness and tuberculosis-related safety profile of interleukin-1 blocking agents in the management of Beh&#xE7;et&#x2019;s disease.</article-title>
<source>Autoimmun Rev</source>. <year>2015</year>;<volume>14</volume>:<fpage>1</fpage>&#x2013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1016/j.autrev.2014.08.008</pub-id><pub-id pub-id-type="pmid">25151975</pub-id></mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
